TP Therapeutics TPX-0005-01 (TRIDENT 1)
- ORGANE :
- COMITE CGFL : XXMULTIORGANE
- PHASE : XXMULTIORGANE
- DATE : 2020-10-01
Médecin : Dr. GHIRINGHELLI
ARC : Hélène Duroux [3460] 03 80 73 75 00
A phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements